+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07708727

Evaluation of Injectable GS-3242 Plus Lenacapavir Compared to Oral Biktarvy in Treatment-Naive People With HIV-1

Led by Gilead Sciences · Updated on 2026-10-13

700

Participants Needed

16

Research Sites

130 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an injectable regimen combining GS-3242 and Lenacapavir LEN compared to the oral drug Biktarvy BFTAF in people with HIV-1 who have not previously received treatment. This study includes Phase 2 and Phase 3 portions with different groups to compare the effectiveness of these treatments over several weeks. The main goal is to measure how well these treatments reduce HIV-1 RNA levels in the blood at specified weeks. Study participants will be assigned to receive either oral loading doses of GS-3242 combined with LEN tablets followed by intramuscular IM injections of both drugs for durations of at least 52 or 104 weeks, depending on the group, or daily oral doses of BFTAF for similar periods. The study includes several treatment groups with varying doses and schedules to assess differences between the injectable and oral regimens. Participants will be monitored regularly with assessments including measuring HIV-1 RNA levels using the US FDA Snapshot Algorithm at weeks 12, 26, 35, 52, and 104, and tracking changes in CD4 cell counts from baseline. Safety is monitored by recording treatment-emergent adverse events throughout the study. The total participation time may extend up to 104 weeks, with frequent visits for medication administration and evaluation of treatment effectiveness and safety.

CONDITIONS

Brief Title

Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

Research Team

G

Gilead Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here